A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 570 participants.

Also called NCT05002933

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 570 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05002933
  • WHO UTN U1111-1251-4484
Other papers using this trial's data
  • Efficacy and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: The INITIATION study Diabetes, obesity & metabolism, 2024-10 DOI, PubMed 39075925

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05002933. Allocation not applicable; no masking; primary purpose treatment. Start 2021-05-20 (actual); primary completion 2023-02-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period
Acronym
INITIATION
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin glargine 300 U/ml
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct05002933
Content hash
40a0ec79aab162c508eaacc839aa7bc2a5529d964685d11ab985488d56d8511a